Showing 454 results

Filters Content type: News, Editors' picks, About HIV Topic: PrEP policies & guidelines

Health service and government policies on the licensing, provision and reimbursement of oral pre-exposure prophylaxis (PrEP). Expert guidelines, based on research evidence, to help clinicians provide care to PrEP users.

PrEP policies & guidelines

Joint Statement: Activists Demand $40-a-Year Generic Price for Breakthrough HIV Prevention Drug Be Made Available to All Low- and Middle Income Countries

Editor's pick
Treatment Action Group
25 September 2025
PrEP policies & guidelines

Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily HIV prevention pill

Editor's pick
Bhekisisa
24 September 2025
Injectable & long-acting PrEP

Support for Indian Manufacturers to Produce Cheap Generics of HIV ‘Miracle’ Drug, Lenacapavir

Editor's pick
Health Policy Watch
24 September 2025
Injectable & long-acting PrEP

CDC 'strongly' backs Gilead's HIV PrEP Yeztugo, but advocacy groups say access barriers remain

Editor's pick
FiercePharma
23 September 2025
PrEP policies & guidelines

UK: Pharmacies must be part of national HIV prevention strategies, researchers urge

Editor's pick
The Pharmaceutical Journal
19 September 2025
Pharmaceutical industry

Lenacapavir in South Africa: There are mounting concerns over transparency in cost

Editor's pick
Health-E News
15 September 2025
PrEP policies & guidelines

U.S. will fulfill Biden-era pledge to provide lenacapavir PrEP to millions

Editor's pick
Science
8 September 2025
Injectable & long-acting PrEP

Why the medical community is thrilled by U.S. support for a 'breakthrough' HIV drug

Editor's pick
NPR
5 September 2025
Injectable & long-acting PrEP

US: CVS Will Not Cover Long-Acting HIV PrEP Lenacapavir For Now

Editor's pick
POZ
5 September 2025
Access to healthcare

PrEP Insurance Denials Occur Frequently in U.S., Nationwide Survey Reveals

Editor's pick
TheBodyPro
4 September 2025
Injectable & long-acting PrEP

South Africa plans anti-HIV jab roll-out at 300+ clinics by April

Editor's pick
Bhekisisa
28 August 2025
Injectable & long-acting PrEP

EU approves Gilead's new injection for preventing HIV

Editor's pick
Reuters
28 August 2025
PrEP policies & guidelines

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

Editor's pick
FiercePharma
25 August 2025
Injectable & long-acting PrEP

We Have More PrEP Options Than Ever In The U.S.—But Who Will Be Able To Afford Them?

Editor's pick
TheBody
25 August 2025
Finance & funding

NIH ponders overhauling HIV budget to capitalize on prevention breakthrough

Editor's pick
Science Magazine
12 August 2025
Treatment guidelines

IAS 2025: Major updates to WHO guidelines: PrEP, injectable ART, infant feeding and prophylaxis and complications including mpox

Editor's pick
i-Base
9 August 2025
PrEP policies & guidelines

Gilead’s Regulatory Delays Block Access to Lenacapavir for PrEP

Editor's pick
Health GAP (Global Access Project)
4 August 2025
PrEP policies & guidelines

With RFK Jr. reportedly weighing preventive services panel revamp, HIV PrEP drugmakers could be at risk: analysts

Editor's pick
FiercePharma
4 August 2025
PrEP

PrEP in Europe

About HIV
July 2025
PrEP policies & guidelines

RFK Jr. reportedly plans to fire the USPSTF for being ‘woke’

Editor's pick
Positively Aware
27 July 2025
Injectable & long-acting PrEP

Does six-monthly PrEP have a future following the collapse of global HIV funding?

News
23 July 2025
Finance & funding

The US cuts challenge African funders and governments to provide new models of PrEP access

News
22 July 2025
Finance & funding

Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year

News
17 July 2025
Injectable & long-acting PrEP

WHO recommends injectable lenacapavir for HIV prevention

Editor's pick
World Health Organization
16 July 2025